Efficacy of Indigo Naturalis in a Multicenter Randomized Controlled Trial of Patients With Ulcerative Colitis

Keyphrases

• Multicenter Randomized Controlled Trial 100%
• Ulcerative Colitis 100%
• Indigo Naturalis 100%
• Placebo 23%
• Clinical Response 23%
• Mucosal Healing 17%
• Mayo Score 17%
• Placebo Groups 11%
• Pulmonary Arterial Hypertension 11%
• Clinical Remission 11%
• Rectal Bleeding 11%
• Daily Dose 5%
• Japan 5%
• Adverse Effects 5%
• Dose Effect 5%
• Regeneration 5%
• Aryl Hydrocarbon Receptor 5%
• Mucosa 5%
• Serious Adverse Events 5%
• Interleukin-22 (IL-22) 5%
• Clinical Trial Registry 5%
• Liver Dysfunction 5%
• Randomized Controlled Trial 5%
• Traditional Chinese Medicine 5%
• Intent-to-treat Analysis 5%
• 3-point 5%
• Randomized Placebo-controlled Trial 5%
• Double-blind Trial 5%
• Active Ulcerative Colitis 5%
• Bleeding Score 5%
• Linear Trend 5%
• Cochran-Armitage Trend Test 5%
• External Reasons 5%
• Main-secondary 5%

Pharmacology, Toxicology and Pharmaceutical Science

• Placebo 100%
• Randomized Controlled Trial 100%
• Ulcerative Colitis 100%
• Adverse Event 28%
• Pulmonary Hypertension 28%
• Remission 28%
• Rectum Hemorrhage 28%
• Aromatic Hydrocarbon Receptor 14%
• Clinical Trial 14%
• Traditional Chinese Medicine 14%
• Mild Hepatic Impairment 14%
• Interleukin 22 14%